文献速递细菌感染、耐药与抗菌药物

改善抗生素可及性的策略及中低收入国家的前进路径

Strategies to improve antibiotic access and a way forward for lower middle-income countries.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

本文综述了抗生素可及性的主要障碍,以及为缓解可及性问题提出并实施的模型,包括市场准入奖励、订阅模式和可转让排他性凭证,并讨论了全球抗生素研发伙伴关系、抗微生物药物耐药行动基金和SECURE平台等全球可及计划,同时提出了改善中低收入国家仿制药和新颖抗生素可及性的前进路径。

要点

  • 抗生素耐药和缺乏有效抗生素可及性显著增加传染病死亡人数。
  • 改善可及性的模型包括市场准入奖励、订阅模式和可转让排他性凭证。
  • 全球可及计划包括全球抗生素研发伙伴关系、抗微生物药物耐药行动基金和SECURE平台。

核心结论

  • 需要大量投资研发并确保可行市场以鼓励创新,才能应对抗生素危机满足未来需求。
  • 尽管全球共同努力下获批或处于不同研发阶段的抗生素数量有所改善,但中低收入国家普遍获取这些基本新型和仿制抗生素仍面临经济激励不足、监管障碍和卫生基础设施薄弱等挑战。
  • 作者提出了改善中低收入国家仿制药和新颖抗生素可及性的前进路径及建议措施。

研究设计与样本

  • 本文为综述,检索范围未在原文中报告。

主要发现

  • 抗生素耐药和缺乏有效抗生素可及性显著增加了传染病死亡人数,使其成为全球健康的最大威胁之一。
  • 中低收入国家普遍获取基本新型和仿制抗生素面临经济激励不足、监管障碍和卫生基础设施薄弱等挑战。
  • 近期保障和扩大可及性的议程已获全球关注,多个机制正被提出和实施以改善基本抗生素可及性。

关键数值与推荐

  • 改善可及性的模型包括但不限于市场准入奖励、订阅模式和可转让排他性凭证。
  • 讨论的全球可及计划包括全球抗生素研发伙伴关系、抗微生物药物耐药行动基金和SECURE平台。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibiotics have substantially improved life expectancy in past decades through direct control or prevention of infections. However, emerging antibiotic resistance and lack of access to effective antibiotics have significantly increased the death toll from infectious diseases, making it one of the biggest threats to global health. Addressing the antibiotic crisis to meet future needs require considerable investment in both research and development along with ensuring a viable marketplace to encourage innovation. Fortunately, there has been some improvement in the number of antibiotics approved or in different phases of development through collective global efforts. However, the universal access to these essential novel and generic antibiotics, especially in low- and middle-income countries (LMICs), is challenged by poor economic incentives, regulatory hurdles and poor health infrastructure. Recently, the agenda of securing and expanding access has gained global attention. Several mechanisms are now being proposed and implemented to improve access to essential antibiotics. This review provides an insight into the major barriers to antibiotic access as well as the models proposed and implemented to mitigate accessibility issues. These models include but are not limited to market entry rewards, subscription models and transferable exclusivity vouchers. Further, global access programmes including, Global Antibiotic Research and Development Partnership, Antimicrobial Resistance Action Fund and SECURE Platform are discussed. We also propose the way forward for improving access in LMICs with suggested measures to improve access to generic and novel antibiotics.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Wasan H, Reeta KH, Gupta YK, et al. Strategies to improve antibiotic access and a way forward for lower middle-income countries. J Antimicrob Chemother. 2024. PMID: 38008421. doi:10.1093/jac/dkad291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。